



Personalis to Participate in the 25th Annual Needham Virtual Conference

April 1, 2026

FREMONT, Calif.--(BUSINESS WIRE)--Apr. 1, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on [LinkedIn](#) and X ([Twitter](#)).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260401441917/en/): <https://www.businesswire.com/news/home/20260401441917/en/>

Investor Relations:

Caroline Corner

investors@personalis.com

415-202-5678

Media:

pr@personalis.com

Source: Personalis, Inc.